Bluebird Bio
Delaware corporation · 3 known investors
Genetix Biotherapeutics (formerly bluebird bio) develops gene therapies for patients with rare genetic diseases including sickle cell disease, beta-thalassemia, and cerebral adrenoleukodystrophy. The therapies use modified blood stem cells to restore function of affected genes and offer potential cures rather than symptom management.
Founders & leadership
DM
David MeekChief Executive Officer
BR
Brian RileyPresident & Chief Technical Officer
JL
Joanne LagerChief Medical Officer
WD
Wendy DiCiccoChief Financial Officer
AC
Adrian ChaissonChief of Staff
DS
Daniel S. LynchDirector
RI
Ramy IbrahimDirector
JC
Jason ColeExecutive Officer
MV
Mark VachonDirector
CB
Chip BairdExecutive Officer
JA
John AgwunobiDirector
DT
Denice TorresDirector
Investors · 3
Reported raises · per SEC filings
Form D private placements▶$75MraisedSep 2021 · 2 investors · BiotechnologyRule 506(b)
▶$75MraisedSep 2021 · 2 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Daniel S. LynchDirector
- Ramy IbrahimDirector
- Jason ColeExecutive Officer
- Mark VachonDirector
- Chip BairdExecutive Officer
- John AgwunobiDirector
- Denice TorresDirector
- William R. SellersDirector
- Nick LeschlyExecutive Officer, Director
- Wendy DixonDirector
- Offering amount
- $75M
- Amount sold
- $75M
- First sale
- Sep 2021
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.